Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Ticker SymbolVOR
Company nameVor Biopharma Inc
IPO dateFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
Number of employees159
Security typeOrdinary Share
Fiscal year-endFeb 05
Address100 Cambridgepark Drive
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02140
Phone16176556580
Websitehttps://www.vorbio.com/
Ticker SymbolVOR
IPO dateFeb 05, 2021
CEODr. Jean-Paul Kress, M.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data